Cabaletta Bio Inc (CABA)

$23.06

-1.26

(-5.18%)

Market is closed - opens 8 PM, 29 Feb 2024

Insights on Cabaletta Bio Inc

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 243.1% return, outperforming this stock by 119.4%

Performance

  • $23.03
    $24.68
    $23.06
    downward going graph

    0.13%

    Downside

    Day's Volatility :6.69%

    Upside

    6.56%

    downward going graph
  • $5.88
    $26.35
    $23.06
    downward going graph

    74.5%

    Downside

    52 Weeks Volatility :77.69%

    Upside

    12.49%

    downward going graph

Returns

PeriodCabaletta Bio IncSector (Health Care)Index (Russel 2000)
3 Months
77.65%
13.2%
0.0%
6 Months
67.03%
9.7%
0.0%
1 Year
175.11%
15.4%
-6.7%
3 Years
112.03%
30.3%
-19.6%

Highlights

Market Capitalization
1.0B
Book Value
$3.86
Earnings Per Share (EPS)
-1.7
Wall Street Target Price
32.44
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-31.99%
Return On Equity TTM
-50.63%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-66.4M
Diluted Eps TTM
-1.7
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.6
EPS Estimate Next Year
-1.72
EPS Estimate Current Quarter
-0.4
EPS Estimate Next Quarter
-0.42

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Cabaletta Bio Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
12
13
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 40.68%

Current $23.06
Target $32.44

Technicals Summary

Sell

Neutral

Buy

Cabaletta Bio Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cabaletta Bio Inc
Cabaletta Bio Inc
5.05%
67.03%
175.11%
112.03%
143.2%
Moderna, Inc.
Moderna, Inc.
-8.24%
-15.49%
-30.7%
-38.88%
325.66%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.93%
19.55%
30.63%
114.52%
130.61%
Novo Nordisk A/s
Novo Nordisk A/s
12.12%
30.39%
73.39%
235.66%
399.41%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-1.12%
22.56%
48.44%
104.83%
128.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cabaletta Bio Inc
Cabaletta Bio Inc
NA
NA
NA
-1.6
-0.51
-0.32
NA
3.86
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.94
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.21
28.21
2.0
44.85
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
45.17
45.17
4.45
3.31
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.25
31.25
0.59
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cabaletta Bio Inc
Cabaletta Bio Inc
Buy
$1.0B
143.2%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$35.9B
325.66%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$107.8B
130.61%
28.21
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$544.3B
399.41%
45.17
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$112.0B
128.3%
31.25
36.68%

Institutional Holdings

  • Fred Alger Management, LLC

    9.94%
  • Adage Capital Partners Gp LLC

    7.62%
  • Cormorant Asset Management, LLC

    6.72%
  • COMMODORE CAPITAL LP

    5.89%
  • BlackRock Inc

    5.70%
  • Deerfield Management Co

    5.46%

Corporate Announcements

  • Cabaletta Bio Inc Earnings

    Cabaletta Bio Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un

Organization
Cabaletta Bio Inc
Employees
92
CEO
Dr. Steven A. Nichtberger M.D.
Industry
Health Technology

FAQs